Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Current Deferred Revenue (2016 - 2023)

Historic Current Deferred Revenue for Fortress Biotech (FBIO) over the last 6 years, with Q1 2023 value amounting to $547000.0.

  • Fortress Biotech's Current Deferred Revenue fell 7310.72% to $547000.0 in Q1 2023 from the same period last year, while for Mar 2023 it was $547000.0, marking a year-over-year decrease of 7310.72%. This contributed to the annual value of $728000.0 for FY2022, which is 7211.8% down from last year.
  • Latest data reveals that Fortress Biotech reported Current Deferred Revenue of $547000.0 as of Q1 2023, which was down 7310.72% from $728000.0 recorded in Q4 2022.
  • Over the past 5 years, Fortress Biotech's Current Deferred Revenue peaked at $7.2 million during Q1 2021, and registered a low of $547000.0 during Q1 2023.
  • In the last 3 years, Fortress Biotech's Current Deferred Revenue had a median value of $2.0 million in 2022 and averaged $2.6 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first plummeted by 6741.2% in 2022, then plummeted by 7310.72% in 2023.
  • Quarter analysis of 3 years shows Fortress Biotech's Current Deferred Revenue stood at $2.6 million in 2021, then tumbled by 72.12% to $728000.0 in 2022, then dropped by 24.86% to $547000.0 in 2023.
  • Its last three reported values are $547000.0 in Q1 2023, $728000.0 for Q4 2022, and $1.1 million during Q3 2022.